title: HEPATOPROTECTIVE EFFECT OF DEXMEDETOMIDINE AGAINST RADIOIODINE TOXICITY IN RATS: EVALUATION OF OXIDATIVE STATUS AND HISTOPATHOLOGICAL CHANGES.
abstract: OBJECTIVE
  Based on the anti-inflammatory, antioxidant and anti-apoptotic properties of DEX, the present study was conducted to investigate the possible radioprotective effects of DEX against hepatic radioiodine (I-131) toxicity.
  
  
  METHODS
  Thirty six rats were randomly divided into three groups as untreated control (group 1); oral radioiodine (RAI, 111 MBq) administrated rats (group 2), and DEX group (oral radioiodine and daily intraperitoneal 25 Âµg/kg DEX administrated rats-group 3). In the third group, DEX administration was started 2 days before and continued for five days after RAI administration. Twenty-four hours after the administration of the last dose of DEX, liver samples were taken for evaluation of oxidative stress parameters and histopathological changes.
  
  
  RESULTS
  The tissue malondialdehyde and advanced oxidation protein product levels in DEX group were significantly lower than RAI group. The total tissue sulphydryl and catalase levels of DEX group were higher than RAI group and the difference was statistically significant. The histopathological damage in the DEX-treated group was significantly less than the damage in the RAI group (p<0.05 for all pathological parameters). Treatment with DEX decreased the histopathological abnormalities when compared with the RAI group.
  
  
  CONCLUSIONS
  It was presented that DEX had radioprotective effect on the liver after I-131 therapy and anti-inflammatory and antioxidant activities are likely to be involved in the mechanism underlying the radioprotective effects of DEX. After further studies, DEX might be used as a hepatoprotective treatment regimen before administering radioactive iodine therapy particularly in patients with hepatic disease.
authors.affiliation: 1 Ankara Education and Research Hospital, Department of General Surgery, Ankara, Turkey.
authors.forename: Kemal
authors.initials: K
authors.lastname: Kismet
authors.affiliation: 2 Ankara Education and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Sadic
authors.affiliation: 1 Ankara Education and Research Hospital, Department of General Surgery, Ankara, Turkey.
authors.forename: Yusuf Murat
authors.initials: YM
authors.lastname: Bag
authors.affiliation: 2 Ankara Education and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey.
authors.forename: Hasan Ikbal
authors.initials: HI
authors.lastname: Atilgan
authors.affiliation: 2 Ankara Education and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey.
authors.forename: Gokhan
authors.initials: G
authors.lastname: Koca
authors.affiliation: 3 Siirt State Hospital, Department of General Surgery, Siirt, Turkey.
authors.forename: Ali Kemal
authors.initials: AK
authors.lastname: Onalan
authors.affiliation: 4 Ankara Education and Research Hospital, Department of Biochemistry, Ankara, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Senes
authors.affiliation: 4 Ankara Education and Research Hospital, Department of Biochemistry, Ankara, Turkey.
authors.forename: Seydi Ali
authors.initials: SA
authors.lastname: Peker
authors.affiliation: 5 Harran University, Faculty of Veterinary Medicine, Department of Pathology, Sanliurfa, Turkey.
authors.forename: Nihat
authors.initials: N
authors.lastname: Yumusak
authors.affiliation: 2 Ankara Education and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey.
authors.forename: Meliha
authors.initials: M
authors.lastname: Korkmaz
keywords: Dexmedetomidine; Liver; histopathology.; oxidative stress; radioiodine